Recombinant Human TNFRSF10B

Catalog # FL026

Product Specifications

Appearance	Sterile filtered White lyophilized (freeze-dried) powder.
Purity	> 97% by SDS-PAGE or HPLC.
Endotoxin	< 0.1 EU/μg of rHusTRAILR2/TNFRSF10B protein as determined by LAL method.
Expression System	Expressed in E. coli.
Species	Human
Tag	Tag free.
Activity	Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24-hour exposur e to LPS (10 ng/mL) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, with 150 mM NaCl, pH 7.4.
Reconstitution	Before use this product, please read the direction below carefully. This vial must be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in a sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
Accession #	O14763 Glu52-Ser183
Amino acid sequence	ESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTR NTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVHKES
Molecular weight	Approximately 14.8 kDa, a single non-glycosylated polypeptide chain containing 132 amino acids.
Synonyms	soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB
Stability & Storage	For long term storage, the product should be stored ≤ -20°C. Please avoid repeated freeze-thaw cycles after reconstitution. 36 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 3 months, -20 to -70°C under sterile conditions after reconstitution.
Precautions	Recombinant Human TNFRSF10B is for research use only and not for use in diagnostic or therapeutic procedures.

Background

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor ne crosis factor-related apoptosis-inducing ligand (TRAIL) -induced cell-death signaling. The death ligand TRAIL bears high potent ial as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients. Recombinant Human soluble TRAILR2/TNFRSF10B is a 14.8kDa protein (132 amino acid) consisting of the TNFR-homologous, cysteine-rich portio n of the extracellular domain.

Validation Images